Division of Developmental Regulation
Department of Genomic Neurology
Publications

Ⅰ.Original articles

 

Yabuki Y, Matsuo K, Kawahata I, Fukui N, Mizobata T, Kawata Y, Owada Y, Shioda N, Fukunaga K. Fatty Acid Binding Protein 3 Enhances the Spreading and Toxicity of α-Synuclein in Mouse Brain. Int J Mol Sci. 21, 2230. (2020)

 

Asamitsu S, Imai Y, Yabuki Y, Ikenoshita S, Takeuchi M, Kashiwagi H, Tanoue Y, Fukuda T, Shioda N. Identification and immunohistochemical characterization of G-quadruplexes in mouse brain. Biochem Biophys Res Commun. in press

 

Wada T, Suzuki S, Shioda N. 5-Aminolevulinic acid can ameliorate language dysfunction of patients with ATR-X syndrome. Congenital Anomalies in press.

 

Shioda N, Imai Y, Yabuki Y, Sugimoto W, Yamaguchi K, Wang Y, Hikida T, Sasaoka T, Mieda M, Fukunaga K. Dopamine D2L Receptor Deficiency Causes Stress Vulnerability through 5-HT1A Receptor Dysfunction in Serotonergic Neurons. J Neurosci. 39, 7551-7563. (2019)

 

Yamada K, Hamashima T, Ishii Y, Yamamoto S, Okuno N, Yoshida N, Yamada M, Huang TT, Shioda N, Tomihara K, Fujimori T, Mori H, Fukunaga K, Noguchi M, Sasahara M. Different PDGF Receptor Dimers Drive Distinct Migration Modes of the Mouse Skin Fibroblast. Cell Physiol Biochem. 51, 1461-1479. (2018)

 

Yamaguchi K, Shioda N, Yabuki Y, Zhang C, Han F, and Fukunaga K. SA4503, A Potent Sigma-1 Receptor Ligand, Ameliorates Synaptic Abnormalities and Cognitive Dysfunction in a Mouse Model of ATR-X Syndrome. Int J Mol Sci. 19, pii: E2811. (2018)

 

Shioda N., Yabuki Y., Yamaguchi K., Onozato M., Li Y., Kurosawa K., Tanabe H., Okamoto N., Era T., Sugiyama H., Wada T. and Fukunaga K. Targeting G-quadruplex DNA as cognitive function therapy for ATR-X syndrome. Nat Med. 24, 802-813. (2018)

 

Tamura S., Okada M., Kato S., Shinoda Y., Shioda N., Fukunaga K., Ui-Tei K. and Ueda M. Ouabagenin is a naturally occurring LXR ligand without causing hepatic steatosis as a side effect. Sci Rep. 8, 2305. (2018)

 

Moriguchi S., Ishizuka T., Yabuki Y., Shioda N., Sasaki Y., Tagashira H., Yawo H., Yeh J., Sakagami H., Narahashi and Fukunaga K. Blockade of the KATP channel Kir6.2 by memantine represents a novel mechanism relevant to Alzheimer’s disease therapy Molecular Psychiatry. 23, 211-221. (2018)

 

Shioda N., Yabuki Y., Wang Y., Uchigashima M., Hikida T., Sasaoka T., Mori H., Watanabe M., Sasahara M. and Fukunaga K. Endocytosis following dopamine D2 receptor activation is critical for neuronal activity and dendritic spine formation via Rabex-5/PDGFRβ signaling in striatopallidal medium spiny neurons. Molecular Psychiatry. 22,1205-1222. (2017)

 

Li Y., Syed J., Suzuki Y., Asamitsu S., Shioda N., Wada T. and Sugiyama H. Effect of ATRX and G-Quadruplex Formation by the VNTR Sequence on α-Globin Gene Expression. Chembiochem. 17, 928-935. (2016)

 

Shioda N., Sawai M., Ishizuka Y., Shirao T. and Fukunaga K. Nuclear Translocation of Calcium/Calmodulin-dependent Protein Kinase IIδ3 Promoted by Protein Phosphatase-1 Enhances Brain-derived Neurotrophic Factor Expression in Dopaminergic Neurons. J Biol Chem. 290, 21663-21675. (2015)

 

Yabuki Y., Shinoda Y., Izumi H., Ikuno T., Shioda N. and Fukunaga K. Dehydroepiandrosterone administration improves memory deficits following transient brain ischemia through sigma-1 receptor stimulation. Brain Res. 1622, 102-113. (2015)

 

Tagashira H., Shinoda Y., Shioda N. and Fukunaga K. Methyl pyruvate rescues mitochondrial damage caused by SIGMAR1 mutation related to amyotrophic lateral sclerosis. Biochim Biophys Acta. 1840, 3320-3334. (2014)

 

Shioda N., Yabuki Y., Kobayashi Y., Onozato M., Owada Y. and Fukunaga K. FABP3 protein promotes α-synuclein oligomerization associated with 1-methyl-1,2,3,6-tetrahydropiridine-induced neurotoxicity. J Biol Chem. 289, 18957-18965. (2014)

 

Yabuki Y., Shioda N., Maeda T., Hiraide S., Togashi H. and Fukunaga K. Aberrant CaMKII activity in the medial prefrontal cortex is associated with cognitive dysfunction in ADHD model rats. Brain Res. 1557, 90-100. (2014)

 

Tagashira H., Bhuiyan M.S., Shioda N. and Fukunaga K. Fluvoxamine rescues mitochondrial Ca2+ transport and ATP production through σ(1)-receptor in hypertrophic cardiomyocytes. Life Sci. 95, 89-100. (2014)

 

Yabuki Y., Shioda N., Yamamoto Y., Shigano M., Kumagai K., Morita M. and Fukunaga K. Oral L-citrulline administration improves memory deficits following transient brain ischemia through cerebrovascular protection. Brain Res. 1520, 157-167. (2013)

 

Yabuki Y., Nakagawasai O., Moriguchi S., Shioda N., Onogi H., Tan-No K., Tadano T. and Fukunaga K. Decreased CaMKII and PKC activities in specific brain regions are associated with cognitive impairment in neonatal ventral hippocampus-lesioned rats. Neuroscience. 234, 103-115. (2013)

 

Yamamoto Y., Shioda N., Han F., Moriguchi S. and Fukunaga K. The Novel Cognitive Enhancer ST101 Enhances Acetylcholine Release in Mouse Dorsal Hippocampus Through T-type Voltage-Gated Calcium Channel Stimulation. J Pharmacol Sci. 121, 212-226. (2013)

 

Shioda N., Ishikawa K., Tagashira H., Ishizuka T., Yawo H. and Fukunaga K. Expression of a truncated form of the endoplasmic reticulum chaperone protein, σ1 receptor, promotes mitochondrial energy depletion and apoptosis. J Biol Chem. 287, 23318-23331. (2012)

 

Moriguchi S., Shioda N., Yamamoto Y., Tagashira H. and Fukunaga K. The T-type voltage-gated calcium channel as a molecular target of the novel cognitive enhancer ST101: enhancement of long-term potentiation and CaMKII autophosphorylation in rat cortical slices. J Neurochem. 121, 44-53. (2012)

 

Shioda N., Moriguchi S., Oya T., Ishii Y., Shen J., Matsushima T., Nishijo H., Sasahara M. and Fukuanaga K. Aberrant hippocampal spine morphology and impaired memory formation in neuronal platelet-derived growth factor beta-receptor lacking mice. Hippocampus. 22, 1371-1378. (2012)

 

Shioda N., Beppu H., Fukuda T., Li E., Kitajima I. and Fukunaga K. Aberrant calcium/calmodulin-dependent protein kinase II (CaMKII) activity is associated with abnormal dendritic spine morphology in the ATRX mutant mouse brain. J Neurosci. 31, 346-358. (2011)

 

Nogami T., Beppu H., Tokoro T., Moriguchi S., Shioda N., Fukunaga K., Ohtsuka T., Ishii Y., Sasahara M., Shimada Y., Nishijo H., Li E. and Kitajima, I. Reduced expression of the ATRX gene, a chromatin-remodeling factor, causes hippocampal dysfunction in mice. Hippocampus. 21, 678-687. (2011)

 

Lu Y.M., Huang J., Shioda N., Fukunaga K., Shirasaki Y., Li X.M. and Han F. CaMKIIδB mediates aberrant NCX1 expression and the imbalance of NCX1/SERCA in transverse aortic constriction-induced failing heart. PLoS One. 6, e24724. (2011)

 

Tagashira H., Bhuiya S., Shioda N. and Fukunaga K. Distinct cardioprotective effects of 17β-estradiol and dehydroepiandrosterone on pressure overload-induced hypertrophy in ovariectomized female rats. Menopause. 18, 1317-1326. (2011)

 

Moriguchi S., Oomura Y., Shioda N., Han F., Hori N., Aou S. and Fukunaga K. Ca(2+)/calmodulin-dependent protein kinase II and protein kinase C activities mediate extracellular glucose-regulated hippocampal synaptic efficacy. Mol Cell Neurosci. 46, 101-107. (2011)

 

Shioda N., Yamamoto Y., Watanabe M., Binas B., Owada Y. and Fukunaga K. Heart-type fatty acid binding protein regulates dopamine D2 receptor function in mouse brain. J Neurosci. 30, 3146-3155. (2010)

 

Shioda N., Yamamoto Y., Han F., Moriguchi S., Yamaguchi Y., Hino M. and Fukunaga K. A Novel Cognitive Enhancer, ZSET1446/ST101, Promotes Hippocampal Neurogenesis and Ameliorates Depressive Behavior in Olfactory Bulbectomized Mice. J. Pharmacol. Exp. Ther. 333, 43-50. (2010)

 

Kajihara R., Fukushige S., Shioda N., Tanabe K., Fukunaga K. and Inui S. CaMKII phosphorylates serine 10 of p27 and confers apoptosis resistance to HeLa cells. Biochem Biophys Res Commun. 401, 350-355. (2010)

 

Tagashira H., Bhuiyan M.S., Shioda N., Hasegawa H., Kanai H. and Fukunaga K. Sigma-1 receptor stimulation with fluvoxamine ameliorates transverse aortic constriction-induced myocardial hypertrophy and dysfunctions in mice. Am J Physiol Heart Circ Physiol. 299, H1535-1545. (2010)

 

Bhuiyan M.S., Tagashira H., Shioda N. and Fukunaga K. Targeting sigma-1 receptor with fluvoxamine ameliorates pressure-overload-induced hypertrophy and dysfunctions. Expert Opin Ther Targets. 14, 1009-1022. (2010)

 

Lu Y.M., Shioda N., Yamamoto Y., Han F. and Fukunaga K. Transcriptional upregulation of calcineurin Abeta by endothelin-1 is partially mediated by calcium/calmodulin-dependent protein kinase IIdelta3 in rat cardiomyocytes. Biochim. Biophys. Acta. 1799, 429-441. (2010)

 

Moriguchi S., Shioda N., Yamamoto Y. and Fukunaga K. Platelet-activating factor-induced synaptic facilitation is associated with increased calcium/calmodulin-dependent protein kinase II, protein kinase C and extracellular signal-regulated kinase activities in the rat hippocampal CA1 region. Neuroscience. 166, 1158-1166. (2010)

 

Lu Y.M., Han F., Shioda N., Moriguchi S., Shirasaki Y., Qin Z.H. and Fukunaga K. Phenylephrine-induced cardiomyocyte injury is triggered by superoxide generation through uncoupled endothelial nitric-oxide synthase and ameliorated by 3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl] -5,6-dimethoxyindazole (DY-9836), a novel calmodulin antagonist. Mol. Pharmacol. 75, 101-112. (2009)

 

Bhuiyan M.S., Shioda N., Shibuya M., Iwabuchi Y. and Fukunaga K. Activation of endothelial nitric oxide synthase by a vanadium compound ameliorates pressure overload-induced cardiac injury in ovariectomized rats. Hypertension 53, 57-63. (2009)

 

Lu Y.M., Shioda N., Han F., Kamata A., Shirasaki Y., Qin Z.H. and Fukunaga K. DY-9760e inhibits endothelin-1-induced cardiomyocyte hypertrophy through inhibition of CaMKII and ERK activities. Cardiovasc. Ther. 27, 17-27. (2009)

 

Han F., Nakano T., Yamamoto Y., Shioda N., Lu Y.M. and Fukunaga K. Improvement of depressive behaviors by nefiracetam is associated with activation of CaM kinases in olfactory bulbectomized mice. Brain Res. 1265, 205-214. (2009)

 

Bhuiyan M.S., Shioda N. and Fukunaga K. Chronic beta-AR activation-induced calpain activation and impaired eNOS-Akt signaling mediates cardiac injury in ovariectomized female rats. Expert Opin. Ther. Targets. 13, 275-286. (2009)

 

Moriguchi S., Shioda N., Han F., Yeh J.Z., Narahashi T. and Fukunaga K. Galantamine enhancement of long-term potentiation is mediated by calcium/calmodulin-dependent protein kinase II and protein kinase C activation. Hippocampus. 19, 844-854. (2009)

 

Oyagi A., Oida Y., Kakefuda K., Shimazawa M., Shioda N., Moriguchi S., Kitaichi K., Nanba D., Yamaguchi K., Furuta Y. Fukunaga K, Higashiyama S and Hara H. Generation and Characterization of Conditional Heparin-Binding EGF-Like Growth Factor Knockout Mice. PLoS One. 4, e7461. (2009)

 

Moriguchi S., Han F., Shioda N., Yamamoto Y., Nakajima T., Nakagawasai O., Tadano T., Yeh J.Z., Narahashi T. and Fukunaga K. Nefiracetam activation of CaM kinase II and protein kinase C mediated by NMDA and metabotropic glutamate receptors in olfactory bulbectomized mice. J Neurochem. 110, 170-181. (2009)

 

Yamamoto Y., Shioda N., Han F., Moriguchi S., Yokosuka A., Mimaki Y., Sashida Y., Yamakuni T., Ohizumi Y. and Fukunaga K. Nobiletin improves brain ischemia-induced learning and memory deficits through stimulation of CaMKII and CREB phosphorylation. Brain Res. 1295, 218-229. (2009)

 

Shioda N., Han F., Morioka M. and Fukunaga K. Bis(1-oxy-2-pyridinethiolato) oxovanadium(IV) enhances neurogenesis via phosphatidylinositol 3-kinase/Akt and extracellular signal regulated kinase activation in the hippocampal subgranular zone after mouse focal cerebral ischemia. Neuroscience 155, 876-887. (2008)

 

Han F., Shioda N., Moriguchi S., Qin Z.H. and Fukunaga K. Downregulation of glutamate transporters is associated with elevation in extracellular glutamate concentration following rat microsphere embolism. Neurosci. Lett. 430, 275-280. (2008)

 

Han F., Shioda N., Moriguchi S., Yamamoto Y, Raie AY, Yamaguchi Y., Hino M. and Fukunaga K. Spiro[imidazo[1,2-a]pyridine-3,2-indan]-2(3H)-one (ZSET1446/ ST101) treatment rescues olfactory bulbectomy-induced memory impairment by activating Ca2+/calmodulin kinase II and protein kinase C in mouse hippocampus. J. Pharmacol. Exp. Ther.. 326, 127-134. (2008)

 

Moriguchi S., Shioda N., Han F., Narahashi T. and Fukunaga K. CaM kinase II and protein kinase C activations mediate enhancement of long-term potentiation by nefiracetam in the rat hippocampal CA1 region. J Neurochem. 106, 1092-1103. (2008)

 

Bhuiyan M.S., Takada Y., Shioda N., Moriguchi S., Kasahara J. and Fukunaga K. Cardioprotective effect of vanadyl sulfate on ischemia/reperfusion-induced injury in rat heart in vivo is mediated by activation of protein kinase B and induction of FLICE-inhibitory protein. Cardiovasc. Ther. 26, 10-23. (2008)

 

Han F., Shioda N., Moriguchi S., Qin Z.H. and Fukunaga K. The vanadium (IV) compound rescues septo-hippocampal cholinergic neurons from neurodegeneration in olfactory bulbectomized mice. Neuroscience 151, 671-679. (2008)

 

Han F., Ali Raie A., Shioda N., Qin Z.H. and Fukunaga K. Accumulation of beta-amyloid in the brain microvessels accompanies increased hyperphosphorylated tau proteins following microsphere embolism in aged rats. Neuroscience 153, 414-427. (2007)

 

Shioda N., Han F., Moriguchi S. and Fukunaga K. Constitutively active calcineurin mediates delayed neuronal death through Fas-ligand expression via activation of NFAT and FKHR transcriptional activities in mouse brain ischemia. J Neurochem. 102, 1506-1517. (2007)

 

Shioda N., Ishigami T., Han F., Moriguchi S., Shibuya M., Iwabuchi Y. and Fukunaga K. Activation of phosphatidylinositol 3-kinase/protein kinase B pathway by a vanadyl compound mediates its neuroprotective effect in mouse brain ischemia. Neuroscience 148, 221-229. (2007)

 

Bhuiyan M.S., Shibuya M., Shioda N., Moriguchi S., Kasahara J., Iwabuchi Y. and Fukunaga K. Cytoprotective effect of bis(1-oxy-2-pyridinethiolato)oxovanadiun(IV) on myocardial ischemia/reperfusion injury elicits inhibition of Fas ligand and Bim expression and elevation of FLIP expression. Eur. J. Pharmacol. 571, 180-188. (2007)

 

Lu Y.M., Shioda N., Han F., Moriguchi S., Kasahara J., Shirasaki Y., Qin Z.H. and Fukunaga K. Imbalance between CaM kinase II and calcineurin activities impairs caffeine-induced calcium release in hypertrophic cardiomyocytes. Biochem Pharmacol. 74, 1727-1737. (2007)

 

Bhuiyan M.S., Shioda N. and Fukunaga K. Ovariectomy augments pressure overload-induced hypertrophy associated with changes in Akt and nitric oxide synthase signaling pathways in female rats. Am. J. Physiol. Endocrinol Metab. 293, 1606-1614. (2007)

 

Moriguchi S., Shioda N., Maejima H., Zhao X., Marszalec W., Yeh J.Z. Fukunaga K and Narahashi T. Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor. Mol. Pharmacol. 71, 580-587. (2007)

 

Shioda N., Moriguchi S., Shirasaki Y. and Fukunaga K. Generation of constitutively active calcineurin by calpain contributes to delayed neuronal death following mouse brain ischemia. J Neurochem. 98, 310-320. (2006)

 

Sasaki T., Han F., Shioda N., Moriguchi S., Kasahara J., Ishiguro K. and Fukunaga K. Lithium-induced activation of Akt and CaM kinase II contributes to its neuroprotective action in a rat microsphere embolism model. Brain Res. 1108, 98-106. (2006)

 

 

Ⅱ.Review articles

 

Asamitsu S, Yabuki Y, Ikenoshita S, Wada T, Shioda N. Pharmacological prospects of G-quadruplexes for neurological diseases using porphyrins. Biochem Biophys Res Commun. in press

 

Asamitsu S., Shioda N. and Sugiyama H. Switching Off Cancer-Causing Telomerase Using Small Molecules. Cell Chem Biol. 26, 1045-1047. (2019)

 

Asamitsu S., Takeuchi M., Ikenoshita S., Imai Y., Kashiwagi H. and Shioda N. Perspectives for Applying G-Quadruplex Structures in Neurobiology and Neuropharmacology. Int. J. Mol. Sci. 20, 2884. (2019)

 

Fukunaga K, Izumi H, Yabuki Y, Shinoda Y, Shioda N, Han F. Alzheimer’s disease therapeutic candidate SAK3 is an enhancer of T-type calcium channels. J Pharmacol Sci. 139, 51-58. (2019)

 

Shioda N. and Fukunaga K. Physiological and Pathological Roles of CaMKII-PP1 Signaling in the Brain. Int J Mol Sci. 219, pii: E20. (2017)

 

Shioda N. Dopamine D2L receptor-interacting proteins regulate dopaminergic signaling. J Pharmacol Sci. pii: S1347-8613, 30171-30178. (2017)

Fukunaga K and Shioda N. Novel dopamine D2 receptor signaling through proteins interacting with the third cytoplasmic loop. Mol Neurobiol. 45, 144-152. (2012).

 

Shioda N., Takeuchi Y and Fukunaga K. Advanced research on dopamine signaling to develop drugs for the treatment of mental disorders: proteins interacting with the third cytoplasmic loop of dopamine D2 and D3 receptors. J Pharmacol Sci. 114, 25-31. (2010).

 

Shioda N., Han F. and Fukunaga K. Role of Akt and ERK signaling in the neurogenesis following brain ischemia. Int. Rev. Neurobiol. 85, 375-387. (2009).

 

Fukunaga K and Shioda N. Pathophysiological relevance of forkhead transcription factors in brain ischemia. Adv Exp Med Biol. 665, 130-142. (2009).

 

Bhuiyan M.S., Shioda N. and Fukunaga K. Targeting protein kinase B/Akt signaling with vanadium compounds for cardioprotection. Expert Opin Ther Targets. 12, 1217-1227. (2008).

 

Fukunaga K., Han F., Shioda N., Moriguchi S., Kasahara J. and Shirasaki Y. DY-9760e, a novel calmodulin inhibitor, exhibits cardioprotective effects in the ischemic heart. Cardiovasc Drug Rev. 24, 88-100. (2006).

 

Ⅲ Review articles in Japanese

 

Shioda N, Yabuki Y, Asamitsu S. The potential of G-quadruplexes as a therapeutic target for neurological diseases. Nihon Yakurigaku Zasshi. 154, 294-300. (2019)

 

Shioda N. Involvement of G-quadruplexes in neurodegenerative diseases]. Nihon Yakurigaku Zasshi.150,98. (2017)

 

Shioda N. RNA toxicity and RAN translation in repeat expansion disorders. Nihon Yakurigaku Zasshi. 150, 165. (2017)

 

Shioda N., and Fukunaga K. Molecular mechanisms of synapse pathology in ATR-X syndrome. Nihon Yakurigaku Zasshi. 145, 174-177. (2015)

 

Shioda N., and Fukunaga K. Abnormal dendritic spine morphology and its signal transduction mechanisms in mental retardation. Seikagaku. 83, 1113-1117. (2011)

 

Shioda N., Yamamoto, Y., Han, F., Moriguchi, S and Fukunaga, K. Neurochemical mechanisms of a novel Alzheimer’s disease therapeutics on improvement of cognition and depressive behavior. Yakugaku Zasshi. 131, 505-511. (2011)

 

Shioda N. and Fukunaga K. Functional roles of constitutively active calcineurin in delayed neuronal death after brain ischemia. Yakugaku Zasshi. 131, 13-20. (2011)

 

Yamamoto Y., Shioda N., Owada Y. and Fukunaga K. Regulation of dopaminergic neuronal activity by heart-type fatty acid binding protein in the brain. Yakugaku Zasshi. 131, 497-501. (2011)

 

Shioda N., Yamamoto Y., Owada Y. and Fukunaga K. Dopamine D2 receptor as a novel target molecule for heart-type fatty acid binding protein. Nihon Shinkei Seishin Yakurigaku Zasshi. 31, 125-130. (2011)

 

Yamamoto, Y., Shioda N., Han F., Moriguchi S. and Fukunaga, K. Donepezil-induced neuroprotection of acetylcholinergic neurons in olfactory bulbectomized mice. Yakugaku Zasshi. 130, 717-721. (2010)

 

Motohashi K., Yamamoto Y., Shioda N., Kondo H., Owada Y. and Fukunaga K. Role of heart-type fatty acid binding protein in the brain function. Yakugaku Zasshi. 129, 191-195. (2009)

 

Fukunaga K., Shioda N., Morioka M. and Han F. Novel therapeutic strategy for neurogenesis in the neurodegenerative disorders. Nihon Yakurigaku Zasshi. 131, 341-346. (2008)

 

Shioda N., Morioka M. and Fukunaga K. Vanadium compounds enhance adult neurogenesis after brain ischemia Yakugaku Zasshi. 128, 413-417. (2008)